Clinical trial
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After…
NCT00355901 · PDL BioPharma, Inc., Industry · Terminated
Key facts
| NCT number | NCT00355901 |
|---|---|
| Title | An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis |
| Official title | An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis |
| Lead sponsor | PDL BioPharma, Inc., Industry |
| Status | Terminated |
| Study type | Observational |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | Visilizumab (Nuvion®, HuM291) |
| Enrollment | 300 |
| Start date | Sep 1, 2006 |
| Completion | Nov 1, 2012 |
| First posted | Jul 25, 2006 |
| Last update posted | Aug 5, 2008 |
| Countries | Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Ireland, Italy, Netherlands, Norway and 2 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: